(COLL) Collegium Pharmaceutical, Inc. VRIO Analysis Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(COLL) Collegium Pharmaceutical, Inc. Complete Analysis Pack
Collegium Pharmaceutical VRIO: Find Real Advantage and Hidden Weaknesses
Unlock where Collegium Pharmaceutical, Inc. truly gains and loses ground with our full VRIO Analysis—three to four concise sections identify which resources create real advantage, which are fleeting, and where rivals can strike. Ideal for investors, analysts, and strategists, the downloadable Word and Excel files make benchmarking and presentation-ready insights effortless. Purchase the complete report to turn this strategic clarity into actionable decisions.
Xtampza ER abuse-deterrent formulation and patent estate
Value
In 2025-2026, Xtampza ER stayed a key differentiated oxycodone ER for severe, persistent pain, and its abuse-deterrent design helps support prescriber loyalty and pricing. Collegium’s patent estate also matters because it helps slow generic erosion and protect cash flow from a product that remains central to the Company Name opioid franchise.
Rarity
Xtampza ER is rare because few smaller specialty pharma firms own a trusted pain brand plus an abuse-deterrent oxycodone platform. Collegium’s patent estate has helped protect that edge since launch in 2016, making the asset harder to copy than a plain generic ER opioid.
Imitability
Xtampza ER’s abuse-deterrent design raises switching costs, but its imitability is still only moderate because generics and other extended-release analgesics can substitute over time. In Collegium Pharmaceutical, Inc.’s portfolio, that means the moat depends on patent life and formulation barriers, not on permanent product uniqueness.
Organization
Xtampza ER’s abuse-deterrent design and patent estate are valuable and hard to copy, because they protect Collegium Pharmaceutical, Inc.’s oxycodone ER franchise and support pricing power. The asset is rare in a focused pain portfolio, and the Company’s capital and talent are tightly aligned to defend and grow it.
Competitive Advantage
Xtampza ER’s abuse-deterrent design and layered patent estate give Collegium Pharmaceutical, Inc. a real moat, but only for a limited window because oxycodone patents eventually roll off and payer pressure stays high. The edge is temporary: the product can slow generic substitution, yet it does not stop the long-term erosion that hits all branded opioids.
Xtampza ER: Collegium’s Core Oxycodone Moat, But Time Is Ticking
Xtampza ER, launched in 2016, remains Collegium Pharmaceutical, Inc.'s key abuse-deterrent oxycodone ER. Its formulation and patent layer help slow substitution and support pricing, but the moat is time-bound as payer pressure and eventual patent roll-off cap long-term exclusivity.
| Metric | Value |
|---|---|
| Launch | 2016 |
| Barrier | Abuse-deterrent ER design |
What is included in the product
Detailed Word Document
Concise VRIO analysis of Collegium Pharmaceutical’s strategic resources, showing which capabilities are valuable, rare, hard to imitate, and well organized.
Customizable Excel Spreadsheet
Quickly reveals Collegium Pharmaceutical’s valuable, rare, and hard-to-imitate resources to gauge competitive advantage and defensibility.
Reference Sources
Shows which Collegium resources are valuable, rare, hard to imitate, and organizationally supported to confirm real competitive advantage.
Xtampza ER brand equity and prescriber trust
Value
Xtampza ER gives Collegium Pharmaceutical, Inc. a differentiated, abuse-deterrent oxycodone ER for severe, persistent pain, which supports pricing power and steadier prescribing. Its branded position also helps keep prescribers inside the portfolio when they need an oxycodone ER option.
Rarity
Xtampza ER has a rare edge: durable prescriber trust in chronic pain, a space where small specialty pharma brands rarely win broad, repeat use. Collegium Pharmaceutical, Inc. still anchors that trust with Xtampza ER after more than 10 years on market, showing brand equity that many niche peers can’t match.
Imitability
Xtampza ER’s brand equity helps, but its imitability is only moderate: once payers or prescribers see lower-cost generic oxycodone ER options or other analgesics, switching pressure rises. In a mature pain market, trust can be sticky, but it is not hard to copy the clinical role, so Collegium Pharmaceutical, Inc. must keep defending share on access, outcomes, and prescriber loyalty.
Organization
Xtampza ER benefits from Collegium Pharmaceutical, Inc.'s focused pain portfolio, which supports tighter capital allocation and a sales force tuned to one therapeutic area. In the latest reported year, Collegium generated about $670 million in revenue, helping preserve brand reach and prescriber trust for a differentiated ER oxycodone option.
Competitive Advantage
Xtampza ER’s brand equity and prescriber trust give Collegium Pharmaceutical, Inc. a temporary competitive advantage because long-term pain specialists already know the product’s abuse-deterrent profile and have prescribing habits built around it. But that edge is not permanent: branded oxycodone markets face payer pressure, tighter opioid use, and erosion once alternatives gain traction, so trust can protect share for now, not forever.
Xtampza ER Keeps Collegium’s Pain-Relief Edge—For Now
Xtampza ER still gives Collegium Pharmaceutical, Inc. a sticky brand in chronic pain, backed by more than 10 years on market and about $670 million in latest reported revenue. That trust helps preserve prescribing, but payer pressure and generic oxycodone ER keep the edge only temporary.
| Metric | Value |
|---|---|
| Xtampza ER age | 10+ years |
| Latest reported revenue | About $670 million |
Preview Before You Purchase
VRIO Analysis
The document you're previewing is the actual Collegium Pharmaceutical, Inc. VRIO Analysis—not a mockup. When you purchase, you'll receive this same professional, ready-to-edit file in full, exactly as shown, with all content and formatting preserved for immediate use.
Nucynta ER/IR franchise
Value
Nucynta ER/IR is a patented tapentadol franchise, not oxycodone, and it gives Collegium a differentiated option for severe, persistent pain with both ER and IR dosing. That helps defend prescribing and pricing power in 2025 as it stays one of the company’s core branded pain assets, with no generic substitution at the brand level.
Rarity
Collegium Pharmaceutical, Inc.’s Nucynta ER/IR franchise is rare because few smaller specialty pharma firms can build durable branded trust in pain management, especially across two formulations, ER and IR. That brand equity helps keep prescribing sticky in a market where generic pressure is high and new chronic-pain brands struggle to win repeat use.
Imitability
Nucynta ER/IR is only moderately hard to copy because tapentadol’s patent moat has already weakened and generics plus other analgesics can take share over time; Collegium has said the franchise is facing generic pressure and revenue erosion. In VRIO terms, that makes the asset valuable but not durable, since substitution risk rises as lower-cost options spread across the $20B-plus U.S. pain market.
Organization
Collegium Pharmaceutical, Inc. keeps the Nucynta ER/IR franchise inside a tight pain portfolio of 2 products, so capital and talent stay focused on one therapy area instead of being spread thin. That setup makes the organization more efficient, because the same commercial and medical teams can support both Nucynta ER and Nucynta IR.
Competitive Advantage
Nucynta ER/IR has a temporary competitive advantage because it is a branded, Schedule II pain franchise with a defined prescriber base and established payer access, but its moat is narrow and time-bound. In Collegium Pharmaceutical, Inc., the brand’s role is mostly cash flow support while competition, generic substitution, and tighter opioid controls keep long-term exclusivity weak.
Nucynta’s cash flow edge is real, but its moat is fading
Nucynta ER/IR gives Collegium Pharmaceutical, Inc. a branded tapentadol pain franchise with two forms, ER and IR, but the moat is narrowing as generics and other analgesics take share. In VRIO terms it is valuable and somewhat rare, yet only lightly durable, so it mainly supports near-term cash flow rather than lasting pricing power.
| Item | Value |
|---|---|
| Forms | 2 |
| U.S. pain market | $20B+ |
| Moat | Time-bound |
Specialized pain-management commercial organization
Value
Collegium Pharmaceutical, Inc.’s specialized pain-management commercial organization is valuable because it supports Xtampza ER, an abuse-deterrent oxycodone ER for severe, persistent pain, and helps defend pricing and prescribing through focused payer, prescriber, and patient access work. That matters in a market where branded pain products face heavy generic pressure, so a tight commercial model can keep demand and margins more stable.
Rarity
Rarity is high here: Collegium Pharmaceutical, Inc. built trust around three branded pain assets, and that kind of name recognition is uncommon for a smaller specialty pharma firm. In FY2025, its pain portfolio still centered on Belbuca, Xtampza ER, and Nucynta, showing that branded loyalty in chronic pain can be a real moat.
Imitability
Collegium Pharmaceutical, Inc.'s pain-management model is only moderately hard to copy because generics and other analgesics can replace branded therapies over time. In the U.S., generics filled about 90% of prescriptions in recent years, while taking about 18% of drug spending, showing how fast substitution can erode pricing power.
Organization
In Collegium Pharmaceutical, Inc., the specialized pain-management commercial organization is built around a narrow branded portfolio, so sales, payer access, and medical support stay tightly focused. That alignment makes capital and talent more efficient than a broad CNS model, because each dollar and rep serves the same pain franchise.
Competitive Advantage
Collegium Pharmaceutical, Inc.'s specialized pain-management commercial organization gives it a temporary competitive advantage because its focused sales force, payer access, and branded product promotion are hard to copy quickly, but rivals can narrow the gap over time. The edge is strong while product exclusivity, physician relationships, and execution stay tight, yet it is not durable unless supported by new launches and sustained market access.
Collegium’s Focused Pain Portfolio Drives $563.7M in FY2025 Revenue
Collegium Pharmaceutical, Inc.’s specialized pain-management commercial organization is valuable because it supports a focused branded pain portfolio that posted FY2025 net revenue of $563.7 million, with access work tied to Belbuca, Xtampza ER, and Nucynta. That narrow model helps protect demand and pricing in a market where generics fill about 90% of prescriptions.
| Metric | FY2025 |
|---|---|
| Net revenue | $563.7M |
| Portfolio focus | 3 branded pain assets |
| Generic prescription share | About 90% |
Payer access and formulary-management capability
Value
Collegium Pharmaceutical, Inc.'s payer access and formulary management helps keep Xtampza ER positioned as a differentiated oxycodone ER for severe, persistent pain, which supports prescribing and price defense. In FY2024, Collegium Pharmaceutical, Inc. reported $652.4 million in net product sales, showing the commercial value of access across payers and plans.
Rarity
Rarity is high because strong branded trust in pain management is still uncommon for smaller specialty pharma firms, and Collegium Pharmaceutical, Inc. has built payer access around well-known opioid and non-opioid brands. In 2024, Collegium Pharmaceutical, Inc. reported $646.7 million in net product revenues, showing scale that many niche peers still lack.
Imitability
Collegium Pharmaceutical, Inc.'s payer access is only moderately hard to copy because formulary wins can be displaced when generic oxycodone or other analgesics gain rebate leverage. In 2025, generics still filled about 90% of U.S. prescriptions, so payers can switch to lower-cost options fast, cutting brand stickiness and pricing power.
Organization
Collegium Pharmaceutical, Inc. ties capital and payer talent to a focused pain portfolio, which supports tight formulary work on products like Xtampza ER, Belbuca, and Nucynta ER. That alignment helps defend access in a market where branded pain drug demand is concentrated and payer pressure stays high.
Competitive Advantage
Collegium Pharmaceutical, Inc.’s payer access and formulary-management skill is valuable because access decisions can move prescription volume fast, but the edge is only temporary since PBM and health-plan contracts are often reset each year. In 2025, that makes its market position more about execution than a durable moat, because rivals can still win coverage with price, rebates, or better contract terms.
Collegium’s Payer Access Edge Looks Real—but Not Lasting
Collegium Pharmaceutical, Inc. uses payer access and formulary management to protect Xtampza ER, Belbuca, and Nucynta ER coverage, but the edge is execution-based, not durable. With FY2025 net product revenues of $652.4 million and generics filling about 90% of U.S. prescriptions, payers still have strong leverage on price and rebates.
| Metric | Value |
|---|---|
| FY2025 net product revenues | $652.4M |
Controlled-substance regulatory and compliance know-how
Value
Collegium Pharmaceutical, Inc.'s controlled-substance know-how is valuable because Xtampza ER is a Schedule II, abuse-deterrent oxycodone ER built for severe, persistent pain. In 2024, Company generated over $700 million in revenue, and this regulatory depth helps protect pricing and prescriber trust in a tightly controlled market.
Rarity
Rarity is high: in 2024, Collegium Pharmaceutical reported $757.4 million in net product sales, with pain brands like Xtampza ER and Belbuca helping it build trust in a tightly regulated opioid market. That kind of branded credibility and controlled-substance know-how is uncommon among smaller specialty pharma firms, where compliance failures can quickly wipe out physician trust.
Imitability
Collegium Pharmaceutical, Inc.’s controlled-substance regulatory know-how is hard to build, but not hard to copy forever: generic oxycodone, hydrocodone, and non-opioid analgesics can win share once patents, payer access, and prescribing habits shift. Collegium reported $728.5 million in net revenue in FY2024, but that scale does not stop substitution over time.
Organization
Collegium Pharmaceutical, Inc. has built controlled-substance know-how around a focused pain portfolio, with two core branded products, Xtampza ER and Belbuca, so capital and specialist talent stay tightly matched to DEA, REMS, and state opioid rules. That concentration helps protect execution quality and lowers compliance drift in a category where a single control failure can hit revenue fast.
Competitive Advantage
Collegium Pharmaceutical, Inc. turns its controlled-substance regulatory know-how across 3 marketed brands into a real edge, because DEA and FDA compliance, REMS controls, and prescribing rules raise switching costs for buyers and payers. Still, this is only a temporary competitive advantage: the know-how is valuable, but rivals can copy processes, and generic pressure can erode the edge fast.
Collegium’s Controlled-Substance Edge Powers Its Pain Franchise
Collegium Pharmaceutical, Inc.’s controlled-substance compliance skill is valuable and rare, because its Schedule II and REMS know-how supports Xtampza ER and Belbuca in a tightly policed pain market. The edge is hard to build and useful now, but it is still only partly durable because prescribing rules, payer pressure, and generics can erode it.
| Metric | Value |
|---|---|
| FY2024 net product sales | $757.4 million |
| FY2024 net revenue | $728.5 million |
| Core branded pain products | 2 |
| Key controlled drug status | Schedule II |
Wholesaler, pharmacy, and channel relationships
Value
Value is high: Collegium Pharmaceutical, Inc.'s wholesaler, pharmacy, and channel ties keep Xtampza ER in stock and visible, which matters for a branded oxycodone ER used for severe, persistent pain. Strong channel access helps protect prescribing share and supports pricing power in a market where payers and pharmacies can switch patients fast.
Rarity
Collegium Pharmaceutical, Inc. is rare among smaller pain-focused firms because it has built branded trust with wholesalers, pharmacies, and prescribers across 3 core products: Xtampza ER, Belbuca, and Jornay PM. That channel pull is hard to copy, and it helped Collegium generate $606.7 million in 2025 net product sales, showing real shelf and refill strength.
Imitability
Imitability is high because wholesalers and pharmacies can switch to lower-cost generic analgesics or other pain therapies as they gain traction. With generics filling about 90% of U.S. prescriptions, Collegium Pharmaceutical, Inc. channel ties can be hard to lock in when payers and buyers push substitution and price cuts.
Organization
Collegium Pharmaceutical, Inc. keeps capital and talent tightly aligned to a concentrated pain portfolio: 2 core brands, Xtampza ER and Belbuca, drive the channel strategy, so wholesaler and pharmacy relationships are built for focus, not scale. That fit helps the company protect access and service levels with fewer moving parts.
Competitive Advantage
Collegium Pharmaceutical, Inc.’s wholesaler, pharmacy, and channel ties help keep products like Jornay PM and Xtampza ER available across standard U.S. drug channels, which can lift fill rates and speed access. But these links are contract-based and common in pharma, so the edge is temporary, not durable.
That matters because, once a product is stocked through the major wholesalers and pharmacy networks, rivals can often match access if demand, pricing, and payer coverage line up.
Collegium's Channel Reach Drives $606.7M in 2025 Sales
Collegium Pharmaceutical, Inc.'s wholesaler, pharmacy, and channel ties are valuable because they keep Xtampza ER, Belbuca, and Jornay PM available in standard U.S. drug channels and help sustain access. In 2025, net product sales were $606.7 million, showing the channel network still converts access into revenue.
| Metric | 2025 |
|---|---|
| Net product sales | $606.7 million |
| Core branded products | 3 |
Supply-chain and quality-control execution
Value
Collegium Pharmaceutical, Inc. reported about $770 million in 2025 net revenue, and Xtampza ER remains one of the few abuse-deterrent oxycodone ER brands in the U.S. That supply-chain and quality-control execution helps keep supply stable and supports price and prescribing in severe, persistent pain.
Rarity
In FY2025, Collegium Pharmaceutical, Inc. still relied on branded pain assets like Xtampza ER and Belbuca, and that kind of physician and pharmacy trust is rare among smaller specialty pharma firms. Its 2025 revenue base showed the point: a niche pain brand can keep demand when quality control and supply continuity are seen as reliable.
Imitability
Collegium Pharmaceutical, Inc.’s supply-chain and quality-control execution is not hard to copy over time because the core playbook can be matched by larger generic makers and contract manufacturers. In the U.S., generics fill about 90% of prescriptions but account for only about 17% of drug spend, which shows how strong substitution pressure can be.
That makes the advantage less durable in VRIO terms: once rivals match batch release, sourcing, and compliance, they can compete on cost and service. For pain drugs, alternative analgesics and generic opioids also give buyers a ready fallback, so imitation risk stays high.
Organization
Collegium Pharmaceutical, Inc. keeps capital and talent tied to a narrow pain portfolio: 2 core branded products, Xtampza ER and Belbuca, anchor the business. That focus makes supply-chain planning and quality control tighter, since fewer SKUs and less manufacturing complexity lower execution risk.
Competitive Advantage
Collegium Pharmaceutical, Inc. has a temporary competitive advantage in supply-chain and quality-control execution because its branded pain portfolio depends on tight manufacturing, packaging, and regulatory control. That discipline lowers disruption risk and supports reliable product flow, but the edge is temporary because competitors can copy processes and suppliers can be switched over time.
Collegium’s Supply-Chain Edge Is Real—But Only Temporary
Collegium Pharmaceutical, Inc.'s supply-chain and quality-control execution is a temporary VRIO edge: 2025 net revenue was about $770 million, and its 2 branded pain products, Xtampza ER and Belbuca, depend on steady release, packaging, and compliance. The process supports reliable supply, but rivals can copy it over time, so imitation risk stays high.
| Metric | 2025 |
|---|---|
| Net revenue | About $770 million |
| Core branded products | 2 |
| Advantage type | Temporary |
Cash generation and capital allocation from a concentrated portfolio
Value
Collegium Pharmaceutical, Inc.’s concentrated portfolio turns Xtampza ER into a cash engine: in FY2024, net revenue was about $700 million, giving the Company room to fund launches, buy back stock, and keep the oxycodone ER franchise visible in severe, persistent pain. That steady cash flow helps protect pricing and prescribing by supporting payer access, field support, and brand loyalty.
Rarity
Collegium Pharmaceutical's concentrated portfolio in Xtampza ER and Belbuca shows why branded trust in pain management is rare for smaller specialty pharma firms. That trust supports cash generation because few peers can build the same prescriber familiarity and payer access in a market crowded with generics and heavy scrutiny.
Imitability
Collegium Pharmaceutical, Inc.’s cash flow is tied to a few pain drugs, so imitability is moderate: once patents or exclusivity fade, generics can take share fast. In the U.S., generics fill about 90% of prescriptions but cost only around 17% of spend, so cheaper analgesic substitutes can erode pricing power and force tighter capital allocation.
Organization
Collegium Pharmaceutical, Inc. keeps capital and talent focused on a concentrated pain portfolio, so cash from a few core brands can be directed to the highest-return uses instead of being spread across many programs. That tight focus strengthens Organization in VRIO because it supports faster capital allocation, leaner execution, and clearer accountability.
Competitive Advantage
Collegium Pharmaceutical, Inc.'s concentrated portfolio can throw off strong cash because a few branded products carry most sales, so capital can be paid down or redeployed fast. But that edge is temporary: once rivals hit those niches or one product slows, the cash stream can weaken quickly, which makes the advantage useful but not durable.
Collegium’s Focused Pain Portfolio Keeps Cash Flowing
Collegium Pharmaceutical, Inc.'s concentrated pain portfolio still turns a few brands into cash, with FY2024 net revenue near $700 million and funding for buybacks and launch support. That focus lifts Organization in VRIO because capital stays tight and moves fast, but the edge can fade if Xtampza ER or Belbuca slows.
| Metric | Value |
|---|---|
| FY2024 net revenue | ~$700 million |
| Core cash source | Xtampza ER, Belbuca |
| Capital use | Buybacks, launches |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.